COMMUNIQUÉS West-GlobeNewswire

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
27/04/2026
- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier - WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a [...]
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
27/04/2026
A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6) Persistence observed through [...]
Intellia Announces Proposed Public Offering of Common Stock
27/04/2026
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
27/04/2026
MINNEAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
27/04/2026
WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
27/04/2026
In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS [...]
ElevateBio to Present Nine Abstracts Showcasing Advancements Across its Gene Editing Platform at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
27/04/2026
– Posters detail large gene insertion and epigenetic editing capabilities, expanding ElevateBio’s gene editing toolbox – Additional presentations highlight protein engineering expertise, off-target assessment strategies [...]
Cellectis présente sa plateforme d’édition épigénétique pour éteindre des gènes sans modifier l’ADN, lors du congrès annuel de l’ASGCT
27/04/2026
NEW YORK, 27 avr. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des [...]
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
27/04/2026
PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically for [...]
Umoja Biopharma Announces Unveiling of UB-VV500 in Upcoming Poster Presentation at the American Society of Gene & Cell Therapy Annual Meeting
27/04/2026
- Industry’s First Combination BCMA x GPRC5D In Vivo CAR T Cell Therapy for the Treatment of Multiple Myeloma - SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a clinical-stage biotechnology [...]
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
27/04/2026
Sheba medical center researcher to present NurExone’s exosome optic nerve regeneration work at ISCEV@Denver TORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) ( [...]
Rgenta Therapeutics Announces Two Oral Presentations Highlighting Proprietary RSwitch Technology at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
27/04/2026
WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for [...]
Outset Medical to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
27/04/2026
SAN JOSE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
27/04/2026
Déclaration de transactions sur actions propres Paris, France (27 avril 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que le 24 avril 2026, les [...]
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
27/04/2026
PRESS RELEASE AB SCIENCE announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors AB Science has reached a final agreement with its financial creditors [...]
Virbac : Rapport Annuel Virbac au 31 décembre 2025 (ESEF)
27/04/2026
Veuillez trouver le Rapport Annuel du Groupe au format ESEF au 31 décembre 2025 Pièce jointe Rapport_Annuel_Virbac_2025_XBRL
AB Science annonce un accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers
27/04/2026
COMMUNIQUE DE PRESSE AB SCIENCE annonce un accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers AB Science est parvenue à un accord définitif avec [...]
Virbac : Public release of Virbac Annual Report at 31 December 2025.
27/04/2026
Public release of Virbac Annual Report at 31 December 2025. The Group released and filed its 2025 Annual Report with the French “Autorité des marchés financiers”, at the ESEF format. Additionally, the report is attached [...]
EssilorLuxottica: Disclosure of transactions in own shares
27/04/2026
Disclosure of transactions in own shares Paris, France (April 27, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2025, EssilorLuxottica declares that on [...]

Pages